Razon Import & Export Co.,Ltd.

Mounjaro® – Once‑Weekly Tirzepatide Injection for Type 2 Diabetes & Weight Management

Mounjaro® contains Tirzepatide, a dual GIP/GLP‑1 receptor agonist indicated for the treatment of type 2 diabetes mellitus and adjunctive weight management. Supplied in pre‑filled, multi‑dose pens, Mounjaro® offers superior glycemic control, weight reduction benefits, and a convenient once‑weekly dosing.

Manufactured under cGMP conditions by Eli Lilly, Mounjaro® is CE‑marked (EU) and FDA‑approved (USA), ensuring premium quality, safety, and efficacy for healthcare providers and patients worldwide.

✅ Product Specifications:
Active Ingredient: Tirzepatide

Dosage Forms: 2.5 mg, 5 mg, 10 mg, 15 mg per 0.5 mL

Presentation: 3 mL multi‑dose pre‑filled pen (4 doses per pen)

Excipients: Sodium phosphate buffer, mannitol, polysorbate 20, water for injection

Shelf Life: 36 months (unopened)

Storage:

Refrigerator (2 °C – 8 °C) until first use

After first use: store at ≤ 30 °C for up to 21 days

Packaging: 1 pen/box or 2 pens/box

⚕️ Indications & Benefits:
Improves glycemic control in adults with type 2 diabetes

Supports clinically meaningful weight loss

Once‑weekly administration enhances patient compliance

Low risk of hypoglycemia when not combined with insulin or sulfonylureas

Backed by SURPASS clinical trial program